Federal Register / Vol. 70, No. 167 / Tuesday, August 30, 2005 / Notices 51355 

comments to Dr. Armitage by mail or 

courier. Commenters planning to attend 

the meeting in person are asked to bring 

35 copies of their comments for public 

distribution. Oral Comments: Requests 

to provide oral comments must be in 

writing (e-mail or fax) and received by 

Dr. Armitage no later than September 

14, 2005 to reserve time on the meeting 

agenda. Presentation time for oral 

comment will typically be about five 

minutes per speaker, but may be 

reduced depending on time availability 

and the number of requests. 

Meeting Accommodations: 

Individuals requiring special 

accommodation to access the public 

meeting listed above should contact the 

DFO at least five business days prior to 

the meeting so that appropriate 

arrangements can be made. 

Dated: August 23, 2005. 

Anthony Maciorowski, 

Acting Director, EPA Science Advisory Board 

Staff Office. 

[FR Doc. 05–17198 Filed 8–29–05; 8:45 am] 

BILLING CODE 6560–50–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[RFA AA169] 

Building for Local Organizations in the 

Republic of South Africa and the 

Kingdoms of Lesotho and Swaziland; 

Notice of Availability of Funds—

Amendment 

A notice announcing the availability 

of Fiscal Year (FY) 2005 funds for a 

cooperative agreement for Building for 

Local Organizations in the Republic of 

South Africa and the Kingdoms of 

Lesotho and Swaziland, was published 

in the Federal Register, August 12, 

2005, Volume 70, Number 155, pages 

47209–47214. 

This notice is amended as follows: 

Page 47210, Approximate Total 

Funding: delete $500,000, and replace 

with $5,000,000. Page 47210, 

Approximate Average Award, delete 

$100,000, and replace with $500,000–

$1,000,000. Page 47210, Ceiling of 

Award Range, delete $100,000, and 

replace with $1,000,000. 

Dated: August 23, 2005. 

William P. Nichols, 

Director, Procurement and Grants Office, 

Centers for Disease Control and Prevention, 

U.S. Department of Health and Human 

Services. 

[FR Doc. 05–17177 Filed 8–29–05; 8:45 am] 

BILLING CODE 4163–18–U 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Vaccines and Related Biological 

Products Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). At least one portion of the 

meeting will be closed to the public. 

Name of Committee: Vaccines and 

Related Biological Products Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held via teleconference on September 

22, 2005 from 1:30 p.m. to 5 p.m. 

Location: NIH campus, Food and Drug 

Administration Bldg. 29B, Conference 

Room C, 8800 Rockville Pike, Bethesda, 

MD. This meeting will be held by 

teleconference. The public is welcome 

to attend the meeting at the above 

location. A speaker phone will be 

provided at the specified location for 

public participation in this meeting. 

Important information about 

transportation and directions to the NIH 

campus, parking, and security 

procedures is available on the internet 

at http://www.nih.gov/about/visitor/ 

index.htm. Visitors must show two 

forms of identification such as a Federal 

employee badge, driver’s license, 

passport, green card, etc. If you are 

planning to drive to and park on the 

NIH campus, you must enter at the 

South Drive entrance of the campus, 

which is located on Wisconsin Ave. (the 

medical center metro entrance), and 

allow extra time for vehicle inspection. 

Detailed information about security 

procedures is located at http:// 

www.nih.gov/about/visitorsecurity.htm. 

Due to the limited available parking, 

visitors are encouraged to use public 

transportation. 

Contact Person: Christine Walsh or 

Denise Royster, Center for Biologics 

Evaluation and Research (HFM–71), 

Food and Drug Administration, 1401 

Rockville Pike, Rockville, MD 20852, 

301–827–0314 or FDA Advisory 

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512391. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: The committee will hear an 

overview of the research of the 

Laboratory of Retroviruses and the 

Laboratory of Immunoregulation, 

Division of Viral Products, and the 

Laboratory of Respiratory and Special 

Pathogens and the Laboratory of 

Methods Development and Quality 

Control, Division of Bacterial Parasitic 

and Allergenic Products, Office of 

Vaccines Research and Review, Center 

for Biologics Evaluation and Research 

(CBER), and in closed session will 

discuss the reports from the Laboratory 

Site Visits of April 18 and 19, 2005, and 

June 16, 2005. 

Procedure: On September 22, 2005, 

from 1:30 p.m. to 4 p.m., the meeting is 

open to the public. Interested persons 

may present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person by September 15, 2005. Oral 

presentations from the public will be 

scheduled between approximately 3 

p.m. to 4 p.m. Time allotted for each 

presentation may be limited. Those 

desiring to make formal oral 

presentations should notify the contact 

person before September 15, 2005, and 

submit a brief statement of the general 

nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation. 

Closed Committee Deliberations: On 

September 22, 2005, from 4 p.m. to 5 

p.m. the meeting will be closed to 

permit discussion where disclosure 

would constitute a clearly unwarranted 

invasion of personal privacy (5 U.S.C. 

552b(c)(6)). The committee will discuss 

a review of internal research programs 

in the Office of Vaccines Research and 

Review, Division of Viral Products and 

Division of Bacterial Parasitic and 

Allergenic Products, CBER. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Christine 

Walsh or Denise Royster (see CONTACT

PERSON) at least 7 days in advance of the 

meeting. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2).